UroGen Pharma (URGN) Enterprise Value (2016 - 2025)
Historic Enterprise Value for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$127.0 million.
- UroGen Pharma's Enterprise Value rose 4910.03% to -$127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.0 million, marking a year-over-year increase of 4910.03%. This contributed to the annual value of -$236.7 million for FY2024, which is 7280.31% down from last year.
- According to the latest figures from Q3 2025, UroGen Pharma's Enterprise Value is -$127.0 million, which was up 4910.03% from -$157.0 million recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Enterprise Value registered a high of -$47.3 million during Q2 2023, and its lowest value of -$249.6 million during Q3 2024.
- Its 5-year average for Enterprise Value is -$135.3 million, with a median of -$127.0 million in 2025.
- As far as peak fluctuations go, UroGen Pharma's Enterprise Value skyrocketed by 5232.18% in 2023, and later tumbled by 40966.79% in 2024.
- Quarter analysis of 5 years shows UroGen Pharma's Enterprise Value stood at -$89.1 million in 2021, then fell by 12.14% to -$100.0 million in 2022, then plummeted by 37.02% to -$137.0 million in 2023, then tumbled by 72.8% to -$236.7 million in 2024, then skyrocketed by 46.33% to -$127.0 million in 2025.
- Its Enterprise Value stands at -$127.0 million for Q3 2025, versus -$157.0 million for Q2 2025 and -$195.9 million for Q1 2025.